Triple agonist (GLP-1 / GIP / glucagon) showing the deepest weight reductions yet seen in Phase 3.
Typical dose range: 2–12 mg
Frequency: Weekly
Route: Subcutaneous
Half-life: ~6 days
Evidence level: Phase 3
Lilly's investigational triple agonist. Reported up to ~24% body-weight reduction at 48 weeks. Still investigational — research only.